IZO:CC - Izotropic Unveils Izoview Commercial Prototype Files New Patents
(TheNewswire)
VANCOUVER, BC – TheNewswire - MAY 10,2022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), acompany commercializing a dedicated breast CT (computed tomography)imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers , is pleased to unveil the commercialprototype device design that will be used in forthcoming clinicalstudies for market authorization in the U.S.
A photorealistic 3D animation detailing IzoView’sdesign, functionality, and capabilities is nowlive on the Company’s YouTube channel at thefollowing link: https://youtu.be/k3hREjHtymk
IzoView has been upgraded and reengineered to deliver astate-of-the-art breast imaging device for the future. The experienceand importance for patients, operators, insurance providers, andcustomers have been further studied in recent months to yield what theCompany believes is a design and functionality that, once approved forsale, will drive demand, acceptance, and market uptake.
A key feature of IzoView’s design is the developmentof self-shielding, which results in radiationemitted during imaging being contained within the device itself,protecting the operator and surrounding physical areas. As theCompany’s first self-shielded design, only the patient's breastbeing imaged is exposed toradiation. IzoView can be safelyoperated in a space where protective barriers and lead partitionscommonly used for CT imaging devices to protectthe operator and surrounding area from radiation exposure are notalways required.
The Company has begun filing patents to protect uniqueand important features of the IzoView Breast CT System. The Companywill co-own these patents with The Regents of the University ofCalifornia, from which Izotropic has the exclusive worldwide licensingrights to Breast CT, including ten other patents and ongoing patentapplications.
ON BEHALF OF THE BOARD
Investor Relations Contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly-tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as "anticipate," "believe,""envision," "estimate," "expect,""intend," "may," "plan,""predict," "project," "target,""potential," "will," "would,""could," "should," "continue," "contemplate" and other similarexpressions and derivations thereof in connection with any discussionof future events, trends or prospects or future operating or financialperformance, although not all forward-looking statements contain theseidentifying words. These statements are not guarantees of performanceand involve risks and uncertainties that are difficult to control orpredict, and as such, they may cause future results of the Company'sactivity to differ significantly from the content and implications ofsuch statements. Forward-Looking Statements are pertinent only as ofthe date on which they are made, and the Company undertakes noobligation to update or revise any Forward-Looking Statements toreflect new information or the occurrence of future events orcircumstances unless otherwise required to do so by law. Neither theCompany nor its shareholders, officers, and consultants shall beliable for any action and the results of any action taken by anyperson based on the information contained herein, including, withoutlimitation the purchase or sale of Company securities. Nothing in thisdocument should be deemed to be medical or other advice of any kind.All images are for illustrative purposes only. IzoView is not yetapproved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.